Alkermes PLC (NAS:ALKS)
$ 29.02 -0.3 (-1.02%) Market Cap: 4.70 Bil Enterprise Value: 4.15 Bil PE Ratio: 14.88 PB Ratio: 3.63 GF Score: 71/100

Alkermes Plc Approval of LYBALVI - Conference Call Transcript

Jun 01, 2021 / 12:30PM GMT
Release Date Price: $21.52 (+2.12%)
Operator

Greetings, and welcome to Alkermes Conference Call to discuss the approval of LYBALVI. My name is Devin, and I will be your conference operator for today. (Operator Instructions)

Please note, this conference is being recorded. I would now like to turn the conference over to your hopes Sandy Coombs, Vice President of Investor Relations. Thank you, Sandy. You may begin.

Sandra Coombs
Alkermes plc - Co-Head of IR

Good morning. Welcome to the Alkermes plc Conference Call to discuss the FDA approval of LYBALVI for the treatment of schizophrenia and bipolar I disorder.

With me today are Richard Pops, our CEO; Blair Jackson, our Chief Operating Officer; and Todd Nichols, our Chief Commercial Officer. Our Chief Medical Officer, Craig Hopkinson, will also join us for the Q&A.

Before we begin, let me remind you that our discussions during this conference call will include forward-looking statements relating to, among other things, our expectations concerning the commercialization of LYBALVI, our future financial expectations and business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot